



Dabrafenib (Tafinlar®)

Lungenkarzinom, nicht-kleinzellig (NSCLC) » + Trametinib » BRAF V600E, Erstlinie

Empfehlungen der Fachgesellschaft zum Einsatz neuer Arzneimittel

Herausgeber

DGHO Deutsche Gesellschaft für Hämatologie und
Medizinische Onkologie e.V.
Bauhofstr. 12
10117 Berlin

Geschäftsführende Vorsitzende: Prof. Dr. med. Claudia Baldus

Telefon: +49 (0)30 27 87 60 89 - 0

info@dgho.de

www.dgho.de

Ansprechpartner

Prof. Dr. med. Bernhard Wörmann
Medizinischer Leiter

Quelle

www.onkopedia.com

Die Empfehlungen der DGHO für die Diagnostik und Therapie hämatologischer und onkologischer Erkrankungen entbinden die verantwortliche Ärztin / den verantwortlichen Arzt nicht davon, notwendige Diagnostik, Indikationen, Kontraindikationen und Dosierungen im Einzelfall zu überprüfen! Die DGHO übernimmt für Empfehlungen keine Gewähr.

Inhaltsverzeichnis

1 Dabrafenib + Trametinib, NSCLC, BRAF V600E, first line	2
---	----------


Dabrafenib (Tafinlar®)

Dokument: Fact Sheet

Spezifizierung: Lungenkarzinom, nicht-kleinzellig (NSCLC) » + Trametinib » BRAF V600E, Erstlinie

Stand: Juli 2021

1 Dabrafenib + Trametinib, NSCLC, BRAF V600E, first line

Dabrafenib + Trametinib, NSCLC, BRAF V600E, first line																																																													
		Facts	Appraisal																																																										
		EU Approval 2017																																																											
<table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="border: none;">Parameter</th> <th style="border: none;">Results¹⁴</th> <th style="border: none;">HR¹⁵</th> <th style="border: none;">p value</th> </tr> </thead> <tbody> <tr> <td style="border: none;">RR²</td> <td style="border: none; text-align: center;">61</td> <td style="border: none;"></td> <td style="border: none;"></td> </tr> <tr> <td style="border: none;">PFS³</td> <td style="border: none; text-align: center;">n.d.¹⁷</td> <td style="border: none;"></td> <td style="border: none;"></td> </tr> <tr> <td style="border: none;">OS⁵</td> <td style="border: none; text-align: center;">24.6</td> <td style="border: none;"></td> <td style="border: none;"></td> </tr> </tbody> </table>	Parameter	Results ¹⁴	HR ¹⁵	p value	RR ²	61			PFS ³	n.d. ¹⁷			OS ⁵	24.6			<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="border: none;">Evidence (LoE)</td> <td style="text-align: center;">5</td><td style="text-align: center;">4</td><td style="text-align: center;">3b</td><td style="text-align: center;">3a</td><td style="text-align: center;">2c</td><td style="text-align: center; background-color: black;">2b</td><td style="text-align: center;">2a</td><td style="text-align: center;">1b</td><td style="text-align: center;">1a</td> </tr> <tr> <td style="border: none;">Clinical benefit (ESMO MCBS)</td> <td style="text-align: center;">1</td><td style="text-align: center; background-color: yellow;">2</td><td style="text-align: center;">3</td><td style="text-align: center;">4</td><td style="text-align: center;">5</td> <td colspan="5" style="border: none;"></td> </tr> <tr> <td colspan="10" style="border: none;"> <div style="display: flex; justify-content: space-between; width: 100%;"> ■ curative ■ non-curative </div> </td> </tr> <tr> <td style="border: none;">Additional benefit (G-BA)</td> <td style="text-align: center;">lower</td><td style="text-align: center;">not proven</td><td style="text-align: center;">not quantifiable</td><td style="text-align: center;">minor</td><td style="text-align: center;">considerable</td><td style="text-align: center;">major</td> <td colspan="4" style="border: none;"></td> </tr> </table>			Evidence (LoE)	5	4	3b	3a	2c	2b	2a	1b	1a	Clinical benefit (ESMO MCBS)	1	2	3	4	5						<div style="display: flex; justify-content: space-between; width: 100%;"> ■ curative ■ non-curative </div>										Additional benefit (G-BA)	lower	not proven	not quantifiable	minor	considerable	major				
Parameter	Results ¹⁴	HR ¹⁵	p value																																																										
RR ²	61																																																												
PFS ³	n.d. ¹⁷																																																												
OS ⁵	24.6																																																												
Evidence (LoE)	5	4	3b	3a	2c	2b	2a	1b	1a																																																				
Clinical benefit (ESMO MCBS)	1	2	3	4	5																																																								
<div style="display: flex; justify-content: space-between; width: 100%;"> ■ curative ■ non-curative </div>																																																													
Additional benefit (G-BA)	lower	not proven	not quantifiable	minor	considerable	major																																																							
<table border="1" style="width: 100%; border-collapse: collapse;"> <tbody> <tr> <td style="border: none;">Patients</td> <td style="border: none;">BRAf V600E, first line</td> </tr> <tr> <td style="border: none;">Trial</td> <td style="border: none;">Phase 2</td> </tr> <tr> <td style="border: none;">Randomisation</td> <td style="border: none;">- : -</td> </tr> <tr> <td style="border: none;">N¹</td> <td style="border: none;">36</td> </tr> <tr> <td style="border: none;">New Therapy</td> <td style="border: none; color: green;">Dabrafenib + Trametinib</td> </tr> <tr> <td style="border: none;">Control</td> <td style="border: none;">-</td> </tr> <tr> <td style="border: none;">Publication</td> <td style="border: none;">DOI:10.1016/S1470-2045(17)30679-4</td> </tr> </tbody> </table>	Patients	BRAf V600E, first line	Trial	Phase 2	Randomisation	- : -	N ¹	36	New Therapy	Dabrafenib + Trametinib	Control	-	Publication	DOI:10.1016/S1470-2045(17)30679-4																																															
Patients	BRAf V600E, first line																																																												
Trial	Phase 2																																																												
Randomisation	- : -																																																												
N ¹	36																																																												
New Therapy	Dabrafenib + Trametinib																																																												
Control	-																																																												
Publication	DOI:10.1016/S1470-2045(17)30679-4																																																												

Legende:

¹ N - number of patients

² RR - remission rate, in %

³ PFS - progression-free survival in months

⁵ OS - overall survival in months

¹⁴ results for control, results for new therapy

¹⁵ hazard ratio for new therapy

¹⁷ n. d. not determined; CT - chemotherapy